Search

Displaying results 4111 - 4120 of 7284 in total
  1. Drug

    Benzhydrocodone

    go.drugbank.com/drugs/DB15465
    Approved

    Benzhydrocodone is a benzylic prodrug of hydrocodone.[L4894] It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse. … It was first approved by the FDA in February 2018 in combination with [acetaminophen] under the trade name Apadaz, marketed by KVK Tech and developed by KemPharm.[L7859,L7862]

  2. Drug

    Ensifentrine

    go.drugbank.com/drugs/DB16157
    ApprovedInvestigational

    Ensifentrine is a first-in-class, selective dual inhibitor of the phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes. … [L50903] On June 26, 2024, the FDA announced the approval of an inhaled product of ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD) in adults, which allows the drug to be

    Synonyms: 2-(9,10-DIMETHOXY-4-OXO-2-(2,4,6-TRIMETHYLPHENYL)IMINO-6,7-DIHYDROPYRIMIDO(6,1-A)ISOQUINOLIN-3-YL)ETHYLUREA, N-(2-((2E)-9,10-DIMETOXI-4-OXO-2-((2,4,6-TRIMETILFENIL)IMINO)-6,7-DIHIDRO-2H-PIRIMIDO(6,1-A)ISOQUINOLEIN-3(4H)-IL)ETIL)UREA
  3. Drug

    Elosulfase alfa

    go.drugbank.com/drugs/DB09051
    ApprovedInvestigational

    Elosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome. … The recommended dose is 2 mg per kg given intravenously over a minimum range of 3.5 to 4.5 hours, based on infusion volume, once every week.

  4. Drug

    Lotiglipron

    go.drugbank.com/drugs/DB21631
    Investigational

    Lotiglipron has a monoisotopic molecular weight of 574.2 Da. … Lotiglipron is a small molecule drug. The usage of the INN stem '-glipron' in the name indicates that Lotiglipron is a glucagon-like peptide 1 receptor (GLPIR) agonist.

  5. Drug

    CA-074 methyl ester

    go.drugbank.com/drugs/DB07223
    Experimental

    CA-074 methyl ester (CA-074Me) is a cell-permeable cathepsin B inhibitor. It is converted by cellular esterases to CA-074.[A258234,A258239]

    Synonyms: CA 074 Me ester, CA 074 methyl ester
  6. Drug

    Cethromycin

    go.drugbank.com/drugs/DB06419
    Investigational

    Cethromycin is a 3-keto (ketolide) derivative of erythromycin A with an 11,12-carbamate group and an O-6-linked aromatic ring system. … [L14006, A203369] However, after completing phase III clinical trials, it was deemed safe but not sufficiently efficacious by the FDA.

  7. Drug

    Paroxetine

    go.drugbank.com/drugs/DB00715
    ApprovedInvestigational

    Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. … [T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.

    Products: PAROXETIN 1A PHARMA 10MG, PAROXETIN 1A PHARMA 20MG
  8. Drug

    Lonafarnib

    go.drugbank.com/drugs/DB06448
    ApprovedInvestigational

    [L23414, L23544] Lonafarnib was granted FDA approval on November 20, 2020, and is the first FDA-approved treatment for HGPS and other related progeroid laminopathies.[L23414, L23549] … aberrant farnesylated form of lamin A called progerin in the inner nuclear membrane.

  9. Drug

    Lofexidine

    go.drugbank.com/drugs/DB04948
    ApprovedInvestigational

    [T209] Lofexidine was developed by US Woldmeds LLC and it was approved by the FDA on May 16, 2018.[L2794] … Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992.

  10. Drug

    Somatrem

    go.drugbank.com/drugs/DB09098
    ApprovedWithdrawn

    Such discussion revolves around whether patients' natural disposition of short stature should be considered a medical condition justifying medical treatment with such hormone therapy - especially when